In this article, we review recent research in suprachoroidal drug administration for the treatment of advanced, refractory, retinal disease.
Intravitreal drugs are currently approved for the treatment of both age-related macular degeneration (AMD) and macular oedema resulting from diabetes or vein occlusion. However, the major drawback of these drugs and/or an intravitreal monotherapy strategy is the need for repeated injections, with most of the drugs requiring injections on a monthly to bimonthly basis. In addition, some of the disease stages do not respond adequately to treatment. Thus, there is currently a medical need for new innovative technologies that reduce the requirement for repeated injections and optimise treatment safety. Moreover, to reduce the risk of adverse effects, exposure of the anterior segment should be limited, which can be achieved by a suprachoroidal approach.
In a rabbit model using dynamic contrast-enhanced magnetic resonance imaging, it has been shown that intrascleral catheter infusions expand the suprachoroidal layer. The model drug, gadolinium-diethylenetriaminopentaacetic acid, was rapidly delivered to the macula with limited anterior segment exposure. 1 However, several other approaches to get the drug nearer to the target without diminishing safety did not show convincing results. 2 Finally, using a porcine model, Olsen and co-workers demonstrated that the suprachoroidal space might be the ideal reservoir for sustained-release formulations. Here, a steep concentration gradient can be established for drug diffusion to the target. The authors directly accessed the posterior segment through the suprachoroidal space by using either a rigid or flexible cannula. Interestingly, by positioning a triamcinolone acetonide depot into the suprachoroidal space, pharmacokinetic studies showed local drug concentrations in both the choroid and retina that were high enough to exert positive effects. In addition, the drug stayed in place for up to four months and an excellent safety profile was also demonstrated. 
Method
The use of a microcatheter (iTRACK™ 400) to access and deliver drugs to the suprachoroidal space was first investigated in a porcine model by Olsen et al. 4 These authors evaluated posterior drug administration by catheterising the suprachoroidal space in 93 out of 94 pigs. Over a six-month follow-up, patients were examined with fundus photography, FA and OCT.
Recently, another pilot study by Rizzo and co-workers included eyes with retinal vein occlusion or diffuse diabetic macular oedema accompanied by massive subfoveal hard exudates (SHE) that was unresponsive to multiple intravitreal injections. The eyes underwent a single treatment in which a combination of bevacizumab and triamcinolone was administered to the submacular suprachoroidal space via a microcatheter. The surgical method followed the method described above. The patient follow-up included best corrected visual acuity (BCVA), vascular leakage, macular thickness, extent of hard exudates and the incidence of adverse events.
Result of the Pilot Evaluations and Further Comments
In eyes and macular oedema was significantly reduced (see Figures 1   and 2) . No surgical or postoperative complications were observed.
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Discussion and Conclusions
The catheter technology we report on in this paper is already successfully in use in the human eye for entering Schlemm's canal in glaucoma surgery and for administering hyaluronic acid molecules for dilating the canal. [8] [9] [10] The The drug is administered directly to the posterior pole, thus potentially reducing but not completely avoiding adverse effects in the anterior segment of the globe, such as glaucoma or cataract formation.
Anatomically, the suprachoroidal space as a drug reservoir is ideal to reduce anterior segment adverse effects. The results of this study suggest that the suprachoroidal application of bevacizumab and triamcinolone acetonide to the submacular region is beneficial in both reabsorbing massive hard exudates and in reducing macular thickness in retinal vasculopathies.
Administering therapeutic agents through the suprachoroidal space might be a useful option as it enables direct exposure of the choroid to the drug, potentially increasing choroidal drug levels. However, larger clinical prospective trials are necessary to elucidate whether this is a useful approach in the clinical routine for the patient groups mentioned here. n
